What's new in primary bone tumors

Journal of Bone and Joint Surgery

Volumn 94, Issue 20, 2012, Pages 1913-1919

  Schwab, Joseph H ^a   Springfield, Dempsey S ^a   Raskin, Kevin A ^a   Mankin, Henry J ^a   Hornicek, Francis J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOXORUBICIN; IFOSFAMIDE; PROTEIN TYROSINE KINASE; RNA BINDING PROTEIN EWS; RNA HELICASE; RNA HELICASE A; SOMATOMEDIN; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANEURYSMAL BONE CYST; APOPTOSIS; BONE TUMOR; CANCER INHIBITION; CANCER SURVIVAL; CHONDROSARCOMA; CHORDOMA; EWING SARCOMA; GIANT CELL TUMOR; OSTEOSARCOMA; OVERALL SURVIVAL; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SURVIVAL RATE;

EID: 84867909499     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.L.00955     Document Type: Review

References (55)

1. Kinsey M, Smith R, Iyer AK, McCabe ER, Lessnick SL. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Cancer Res. 2009 Dec 1;69(23):9047-55. Epub 2009 Nov 17.
2. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML, Uren A, Toretsky JA. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma Nat Med. 2009 Jul;15(7):750-6. Epub 2009 Jul 5.
3. France KA, Anderson JL, Park A, Denny CT. Oncogenic fusion protein EWS/FLI1 down-regulates gene expression by both transcriptional and posttranscriptional mechanisms. J Biol Chem. 2011 Jul 1;286(26):22750-7. Epub 2011 Apr 28.
4. Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, Lion T, Poremba C, Marandet J, Ballet S, Pierron G, Brownhill SC, Nesslböck M, Ranft A, Dirksen U, Oberlin O, Lewis IJ, Craft AW, Jürgens H, Kovar H. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol. 2010 Apr 20;28(12):1982-8. Epub 2010 Mar 22.
5. Applebaum MA, Worch J, Matthay KK, Goldsby R, Neuhaus J, West DC, Dubois SG. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer. 2011 Jul 1;117(13):3027-32. doi: 10.1002/cncr.25840. Epub 2011 Jan 10.
6. Pradhan A, Grimer RJ, Spooner D, Peake D, Carter SR, Tillman RM, Abudu A, Jeys L. Oncological outcomes of patients with Ewing's sarcoma: is there a difference between skeletal and extra-skeletal Ewing's sarcoma? J Bone Joint Surg Br. 2011 Apr;93(4):531-6.
7. Gupta AA, Pappo A, Saunders N, Hopyan S, Ferguson P, Wunder J, O'Sullivan B, Catton C, Greenberg M, Blackstein M. Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer. 2010 Jul 1;116(13):3189-94.
8. Haeusler J, Ranft A, Boelling T, Gosheger G, Braun-Munzinger G, Vieth V, Burdach S, van den Berg H, Juergens H, Dirksen U. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer. 2010 Jan 15;116(2):443-50.
9. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, Pandini G, López-Guerrero JA, Schaefer KL, Belfiore A, Picci P, Scotlandi K. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene. 2011 Jun 16;30(24):2730-40. doi: 10.1038/onc.2010.640. Epub 2011 Jan 31.
10. Scotlandi K, Manara MC, Serra M, Marino MT, Ventura S, Garofalo C, Alberghini M, Magagnoli G, Ferrari S, Lopez-Guerrero JA, Llombard-Bosch A, Picci P. Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. Eur J Cancer. 2011 May;47(8):1258-66. Epub 2011 Feb 21.
11. Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res. 2010 Oct 1;70(19):7610-9. Epub 2010 Sep 14.
12. Li Y, Flores R, Yu A, Okcu MF, Murray J, Chintagumpala M, Hicks J, Lau CC, Man TK. Elevated expression of CXC chemokines in pediatric osteosarcoma patients. Cancer. 2011 Jan 1;117(1):207-17. doi: 10.1002/cncr.25563. Epub 2010 Aug 30.
13. Cesari M, Alberghini M, Vanel D, Palmerini E, Staals EL, Longhi A, Abate M, Ferrari C, Balladelli A, Ferrari S. Periosteal osteosarcoma: a single-institution experience. Cancer. 2011 Apr 15;117(8):1731-5. doi: 10.1002/cncr.25718. Epub 2010 Nov 8.
14. Ruggieri P, Calabrò T, Montalti M, Mercuri M. The role of surgery and adjuvants to survival in Pagetic osteosarcoma. Clin Orthop Relat Res. 2010 Nov;468(11): 2962-8.
15. Samartzis D, Nishi N, Hayashi M, Cologne J, Cullings HM, Kodama K, Miles EF, Funamoto S, Suyama A, Soda M, Kasagi F. Exposure to ionizing radiation and development of bone sarcoma: new insights based on atomic-bomb survivors of Hiroshima and Nagasaki. J Bone Joint Surg Am. 2011 Jun 1;93(11):1008-15.
16. Choy E, Hornicek F, MacConaill L, Harmon D, Tariq Z, Garraway L, Duan Z. High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer. 2012 Jun 1;118(11): 2905-14. doi: 10.1002/cncr.26617. Epub 2011 Oct 17.
17. Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC, Araujo DM, Chen K, Zhang W. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer. 2011 Nov 1;117(21): 4925-38. doi: 10.1002/cncr.26116. Epub 2011 Apr 14.
18. Steinmann P, Walters DK, Arlt MJ, Banke IJ, Ziegler U, Langsam B, Arbiser J, Muff R, Born W, Fuchs B. Antimetastatic activity of honokiol in osteosarcoma. Cancer. 2012 Apr 15;118(8):2117-27. doi: 10.1002/cncr.26434. Epub 2011 Sep 20.
19. Hassan SE, Bekarev M, Kim MY, Lin J, Piperdi S, Gorlick R, Geller DS. Cell surface receptor expression patterns in osteosarcoma. Cancer. 2012 Feb 1;118(3):740-9. doi: 10.1002/cncr.26339. Epub 2011 Jul 12.
20. Noh K, Kim KO, Patel NR, Staples JR, Minematsu H, Nair K, Lee FY. Targeting inflammatory kinase as an adjuvant treatment for osteosarcomas. J Bone Joint Surg Am. 2011 Apr 20;93(8):723-32.
21. Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins JJ, Quintana J, Luchtman- Jones L, Villarroel M, Santana VM. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. Cancer. 2011 Jun 15;117(12):2770-8. doi: 10.1002/cncr.25715. Epub 2011 Jan 10.
22. Ciernik IF, Niemierko A, Harmon DC, Kobayashi W, Chen YL, Yock TI, Ebb DH, Choy E, Raskin KA, Liebsch N, Hornicek FJ, Delaney TF. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer. 2011 Oct 1;117(19):4522-30. doi: 10.1002/cncr.26037. Epub 2011 Mar 29.
23. Guo J, Reddick WE, Glass JO, Ji Q, Billups CA, Wu J, Hoffer FA, Kaste SC, Jenkins JJ, Ortega Flores XC, Quintana J, Villarroel M, Daw NC. Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma. Cancer. 2011 Dec 16. doi: 10.1002/cncr.26701. [Epub ahead of print].
24. Magnan H, Chou AJ, Chou JF, Yeung HW, Healey JH, Meyers PA. Noninvasive imaging with thallium-201 scintigraphy may not correlate with survival in patients with osteosarcoma. Cancer. 2010 Sep 1;116(17):4147-51.
25. Ichikawa J, Cole HA, Magnussen RA, Mignemi NA, Butler M, Holt GE, O'Rear L, Yuasa M, Pabla B, Haro H, Cates JM, Hamm HE, Schwartz HS, Schoenecker JG. Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: procoagulant nature of osteosarcoma. Cancer. 2012 May 1;118(9):2494-506. doi: 10.1002/cncr.26518. Epub 2011 Sep 27.
26. Kubo T, Shimose S, Matsuo T, Fujimori J, Arihiro K, Ochi M. Interferon-α/β receptor as a prognostic marker in osteosarcoma. J Bone Joint Surg Am. 2011 Mar 16;93(6):519-26.
27. Meyers PA, Healey JH, Chou AJ, Wexler LH, Merola PR, Morris CD, Laquaglia MP, Kellick MG, Abramson SJ, Gorlick R. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer. 2011 Apr 15;117(8):1736-44. doi: 10.1002/cncr.25744. Epub 2010 Nov 8.
28. Chen C, Zhou H, Liu X, Liu Z, Ma Q. Reduced expression of von Hippel-Lindau protein correlates with decreased apoptosis and high chondrosarcoma grade. J Bone Joint Surg Am. 2011 Oct 5;93(19):1833-40.
29. Nakagawa SA, Lopes A, Lopes de Carvalho A, Rossi BM, Werneck da Cunha I, Soares FA, Chung WT, Alves LA. Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis. J Bone Joint Surg Am. 2010 Jul 21;92(8):1738-46.
30. Donati D, Colangeli S, Colangeli M, Di Bella C, Bertoni F. Surgical treatment of grade I central chondrosarcoma. Clin Orthop Relat Res. 2010 Feb;468(2):581-9. Epub 2009 Aug 29.
31. Souna BS, Belot N, Duval H, Langlais F, Thomazeau H. No recurrences in selected patients after curettage with cryotherapy for grade I chondrosarcomas. Clin Orthop Relat Res. 2010 Jul;468(7):1956-62. Epub 2010 Jan 7.
32. Mohler DG, Chiu R, McCall DA, Avedian RS. Curettage and cryosurgery for lowgrade cartilage tumors is associated with low recurrence and high function. Clin Orthop Relat Res. 2010 Oct;468(10):2765-73. Epub 2010 Jun 24.
33. de Camargo OP, Baptista AM, Atanásio MJ, Waisberg DR. Chondrosarcoma of bone: lessons from 46 operated cases in a single institution. Clin Orthop Relat Res. Nov;468(11):2969-75.
34. Grignani G, Palmerini E, Stacchiotti S, Boglione A, Ferraresi V, Frustaci S, Comandone A, Casali PG, Ferrari S, Aglietta M. A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-a or -b: An Italian Sarcoma Group study. Cancer. 2011 Feb 15;117(4):826-31. doi: 10.1002/cncr.25632. Epub 2010 Oct 5.
35. Goda JS, Ferguson PC, O'Sullivan B, Catton CN, Griffin AM, Wunder JS, Bell RS, Kandel RA, Chung PW. High-risk extracranial chondrosarcoma: Long-term results of surgery and radiation therapy. Cancer. 2011 Jan 18. doi: 10.1002/cncr.25806. [Epub ahead of print].
36. Brown MJ, Kor DJ, Curry TB, Warner MA, Rodrigues ES, Rose SH, Dekutoski MB, Moriarty JP, Long KH, Rose PS. Sacral tumor resection: the effect of surgical staging on patient outcomes, resource management, and hospital cost. Spine (Phila Pa 1976). 2011 Sep 1;36(19):1570-8.
37. Clarke MJ, Dasenbrock H, Bydon A, Sciubba DM, McGirt MJ, Hsieh PC, Yassari R, Gokaslan ZL, Wolinsky JP. Posterior-only approach for en bloc sacrectomy: clinical outcomes in 36 consecutive patients. Neurosurgery. 2012 Aug;71(2):357-64.
38. Fuji H, Nakasu Y, Ishida Y, Horiguchi S, Mitsuya K, Kashiwagi H, Murayama S. Feasibility of proton beam therapy for chordoma and chondrosarcoma of the skull base. Skull Base. 2011 May;21(3):201-6.
39. Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, Gronchi A, Amore P, Vinaccia V, Casali PG. Phase II study of imatinib in advanced chordoma. J Clin Oncol. 2012 Mar 20;30(9):914-20. Epub 2012 Feb 13.
40. Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, Li S, Goldstein AM, Parry DM, Kelley MJ. T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet. 2009 Nov;41(11):1176-8. Epub 2009 Oct 4.
41. Henderson ER, Groundland JS, Pala E, Dennis JA, Wooten R, Cheong D, Windhager R, Kotz RI, Mercuri M, Funovics PT, Hornicek FJ, Temple HT, Ruggieri P, Letson GD. Failure mode classification for tumor endoprostheses: retrospective review of five institutions and a literature review. J Bone Joint Surg Am. 2011 Mar 2;93(5):418-29.
42. Ruggieri P, Mavrogenis AF, Ussia G, Angelini A, Papagelopoulos PJ, Mercuri M. Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor. Clin Orthop Relat Res. 2010 Nov;468(11):2954-61.
43. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3): 275-80. Epub 2010 Feb 10.
44. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg. 2010 May;68(5):959-63. Epub 2010 Feb 10.
45. Won KY, Kalil RK, Kim YW, Park YK. RANK signalling in bone lesions with osteoclast-like giant cells. Pathology. 2011 Jun;43(4):318-21.
46. Zwolak P, Manivel JC, Jasinski P, Kirstein MN, Dudek AZ, Fisher J, Cheng EY. Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. J Bone Joint Surg Am. 2010 Jan;92(1):162-8.
47. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res. 2011 Feb;469(2):591-9. Epub Aug 13.
48. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Recurrent giant cell tumor of long bones: analysis of surgical management. Clin Orthop Relat Res. 2011 Apr;469(4):1181-7. Epub 2010 Sep 16.
49. Ye Y, Pringle LM, Lau AW, Riquelme DN, Wang H, Jiang T, Lev D, Welman A, Blobel GA, Oliveira AM, Chou MM. TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-kappaB. Oncogene. 2010 Jun 24;29(25):3619-29. Epub 2010 Apr 26.
50. Varshney MK, Rastogi S, Khan SA, Trikha V. Is sclerotherapy better than intralesional excision for treating aneurysmal bone cysts? Clin Orthop Relat Res. 2010 Jun;468(6):1649-59. Epub 2009 Oct 23.
51. Steffner RJ, Liao C, Stacy G, Atanda A, Attar S, Avedian R, Peabody TD. Factors associated with recurrence of primary aneurysmal bone cysts: is argon beam coagulation an effective adjuvant treatment? J Bone Joint Surg Am. 2011 Nov 2; 93(21):e1221-9.
52. Pedrini E, De Luca A, Valente EM, Maini V, Capponcelli S, Mordenti M, Mingarelli R, Sangiorgi L, Dallapiccola B. Novel EXT1 and EXT2 mutations identified by DHPLC in Italian patients with multiple osteochondromas. Hum Mutat. 2005 Sep;26(3):280.
53. Zuntini M, Pedrini E, Parra A, Sgariglia F, Gentile FV, Pandolfi M, Alberghini M, Sangiorgi L. Genetic models of osteochondroma onset and neoplastic progression: evidence for mechanisms alternative to EXT genes inactivation. Oncogene. 2010 Jul 1;29(26):3827-34. Epub 2010 Apr 26.
54. Zuntini M, Salvatore M, Pedrini E, Parra A, Sgariglia F, Magrelli A, Taruscio D, Sangiorgi L. MicroRNA profiling of multiple osteochondromas: identification of disease-specific and normal cartilage signatures. Clin Genet. 2010 Dec;78(6):507-16. doi: 10.1111/j.1399-0004.2010.01490.x.
55. Bowen ME, Boyden ED, Holm IA, Campos-Xavier B, Bonafé L, Superti-Furga A, Ikegawa S, Cormier-Daire V, Bovée JV, Pansuriya TC, de Sousa SB, Savarirayan R, Andreucci E, Vikkula M, Garavelli L, Pottinger C, Ogino T, Sakai A, Regazzoni BM, Wuyts W, Sangiorgi L, Pedrini E, Zhu M, Kozakewich HP, Kasser JR, Seidman JG, Kurek KC, Warman ML. Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome. PLoS Genet. 2011 Apr;7(4):e1002050. Epub 2011 Apr 14.